Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms Post author: Post published:November 22, 2023 Post category:uncategorized Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19. You Might Also Like Individuals with periodontitis exhibit unique inflammatory protein profile in the blood September 6, 2024 Stilla Technologies expands U.S. presence through strategic distribution relationship with Avantor and introduces advanced content offerings June 20, 2024 Clozapine improves outcomes in treatment-resistant schizophrenia July 12, 2024
Individuals with periodontitis exhibit unique inflammatory protein profile in the blood September 6, 2024
Stilla Technologies expands U.S. presence through strategic distribution relationship with Avantor and introduces advanced content offerings June 20, 2024